CeQur is dedicated to helping people with diabetes by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company has a platform of an extremely simple, discrete and wearable, 3-day device with the first generation being FDA cleared and CE marked.
In July 2018, CeQur decided to focus its efforts to bring to market a unique and extremely simple 3-day bolus insulin delivery device, called CeQur Simplicity. This device allows a person to administer insulin in a simple, discreet way by just clicking the two buttons. It is extremely slim and is virtually undetectable under clothing. Bolusing can be done over clothing, so there is no reason to step away from friends to discreetly deliver a dose. (www.myceqursimplicity.com). CeQur Simplicity is designed to revolutionize insulin delivery by providing a convenient, discreet and inject free solution to insulin delivery that is easy to teach and prescribe. The word “revolutionize” is key. In a world full of complex devices - Simplicity makes it extremely easy to take insulin and ensure compliance to therapy.
The 3-day bolus device is FDA cleared for adults requiring insulin and is currently in a pilot launch stage in 2021. We are working with select physicians and centers to bring this innovative technology to patients. The CeQur Simplicity device will be available broadly soon. CeQur Simplicity device has been tested in three clinical studies that demonstrated the device is effective, safe and easy to use. Moreover the studies highlighted that it has high patient satisfaction over daily injections and strong participant desire to stay on the wearable bolus device versus going back to injections.
CeQur is headquartered in Horw, Switzerland, with operations in Cardiff, United Kingdom and Marlborough, Massachusetts.
In July 2018, CeQur decided to focus its efforts to bring to market a unique and extremely simple 3-day bolus insulin delivery device, called CeQur Simplicity. This device allows a person to administer insulin in a simple, discreet way by just clicking the two buttons. It is extremely slim and is virtually undetectable under clothing. Bolusing can be done over clothing, so there is no reason to step away from friends to discreetly deliver a dose. (www.myceqursimplicity.com). CeQur Simplicity is designed to revolutionize insulin delivery by providing a convenient, discreet and inject free solution to insulin delivery that is easy to teach and prescribe. The word “revolutionize” is key. In a world full of complex devices - Simplicity makes it extremely easy to take insulin and ensure compliance to therapy.
The 3-day bolus device is FDA cleared for adults requiring insulin and is currently in a pilot launch stage in 2021. We are working with select physicians and centers to bring this innovative technology to patients. The CeQur Simplicity device will be available broadly soon. CeQur Simplicity device has been tested in three clinical studies that demonstrated the device is effective, safe and easy to use. Moreover the studies highlighted that it has high patient satisfaction over daily injections and strong participant desire to stay on the wearable bolus device versus going back to injections.
CeQur is headquartered in Horw, Switzerland, with operations in Cardiff, United Kingdom and Marlborough, Massachusetts.
Location: Switzerland, Lucerne, Horw
Employees: 51-200
Total raised: $335M
Founded date: 2008
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.01.2025 | - | $120M | - |
| 13.04.2021 | Series C | $115M | Endeavour ... |
| 01.09.2015 | Series C | $100M | - |
Mentions in press and media 9
| Date | Title | Description |
| 09.01.2025 | CeQur's $120 Million Leap: A New Era in Diabetes Management | In the world of diabetes management, innovation is the lifeblood. CeQur, a medical device company, has just taken a significant step forward. With a recent $120 million equity financing, CeQur is poised to transform how insulin is delivered... |
| 08.01.2025 | CeQur secures $120 million to scale diabetes management solutions | CeQur Simplicity patch is a discreet, injection-free bolus insulin delivery solution offering a convenient solution to individuals on multiple daily injections. One CeQur Simplicity patch holds up to 200 units of rapid-acting insulin admin... |
| 07.01.2025 | CeQur Closes a $120M Equity Financing to Drive Commercial Growth | CeQur® The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its 4-day wearable insulin delivery device, to more hea... |
| 18.06.2024 | CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management | CeQur Simplicity 4-Day Wearable Insulin Patch The CeQur Simplicity patch is now FDA-cleared for up to 4 days of wear. Each patch replaces up to 12 injections further simplifying mealtime insulin management. HORW, Switzerland, June 18, 2024 ... |
| 13.04.2021 | YPSOMED HOLDING AG CeQur : Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur : Simplicity Wearable Insulin-Delivery Device | CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing. The company will use th... |
| 01.09.2015 | CeQur Raises $100M in Series C Financing | CeQur SA, a Lucerne, Switzerland-based developer of a simple insulin infusion solution for people with diabetes, raised $100m in Series C financing. The round was led by Woodford Investment Management LLP and Arthurian Life Sciences with pa... |
| 10.09.2013 | Diabetes: CeQur closes $27B Series B round | CeQur SA is planning to scale up manufacturing of its PaQ insulin delivery device in Europe with a $27 million Series B round. The Horw, Switzerland-based company said the round was led by a pair of new, private investors and was joined by ... |
| 09.09.2013 | CeQur Closes $27M Series B Financing | CeQur SA, a Horw, Switzerland-based company focused on the development and commercialization of simple insulin delivery devices, closed a $27m Series B financing. The round was led by two new private investors with participation of all curr... |
| 17.10.2012 | CeQur completes clinical study of its Insulin delivery device | PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin mon... |